References:
- Prestipino A, Emhardt AJ, Aumann K, O’Sullivan D, Gorantla
SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Zeiser R. Oncogenic
JAK2V617F causes PD-L1 expression, mediating immune escape in
myeloproliferative neoplasms. Sci Transl Med. 2018 Feb 21;10(429)
- Thiele J, Kvasnicka HM, Tefferi A, Barosi G, Orazi A, Vardiman,et al.
Myelofibrosis. In: Swerdlow SH, Campo E, Harris NL,Jaffe ES, Pileri
SA, Stein H, et al., editors. WHO classification oftumours of
haematopoietic and lymphoid tissues. Lyon:WHO; 2008. p. 44–7.
- Savona MR. Are we altering the natural history of
primarymyelofibrosis? Leuk Res. 2014;38(9):1004–12.
- Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS Coexisting JAK2V617F
and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They
Designate a New Subtype? Asian Pac J Cancer Prey. 2016;17(3):923-6.
- Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U,
Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW. Hematopoietic Cell
Transplantation as Curative Therapy for Patients with Myelofibrosis:
Long-Term Success in all Age Groups. Biol Blood Marrow Transplant.
2015;21(11):1883. Epub 2015 Sep 11.
- Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with
ruxolitinib versus best available therapy for myelofibrosis. N Engl J
Med 2012; 366:787.
- Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind,
placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J
Med 2012; 366:799.
- Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A,
Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K,
Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024
Investigators.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell
Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016
Oct 8.
- Lee, Sze-Hwei., Lin, Chien-Chin., Wie, Chao-Hong., Chang, Ko-Ping.,
Yuan, Chang-Tsu., Tsai, Cheng-Hong., Liu, Jia-Hao. House, Hsin-An.,
Tang, Jih-Lu., Chou, Wen-Chien., Tien, Hwei-Fang. PD-L1 expression in
megakaryocytes and its clinicopathological features in primary
myelofibrosis patients. The journal of Pathology: Clinical Research.
September 2021.
- Hobbs, Gabriela. Bozkus, Cansu Cimen, Moshier, Erin, Doughterty
Mikaela., Bar-Nata, Michal., Sandy, Lonette., Johnson, Kathryn.,
Foster, Julia Elise., Som, Tina., Macrae, Molly., Marble, Hetal.,
Salama, Mohamed., El Jamal, Siraj M., Zubizarreta, Nicole., Wadleigh,
Martha., Stone, Richard., Bhardwaj, Nina., Iancu-Rubin, Camelia.,
Mascarenhas, John. PD-1 inhibiation in advanced myeloproliferative
neoplasms. Blood advances. December 2021.
- Dall, Iman Abou Kantarjian, Jagop., Daver, Naval., Masarova, Lucia.,
Pemmaraju, Naveen. Bose, prithivaj., Garcia-Manero, Guillermo.,
Verstovsek, Srdan. Phase II study of single agente nivoulmab in
patients with myelofibrosis. Ann Hematol. December 2021.